Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
IPO Year: 2013
Exchange: NASDAQ
Website: aeriepharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/29/2022 | $14.00 → $15.25 | Buy → Neutral | Citigroup |
| 8/23/2022 | Buy → Hold | Needham | |
| 8/23/2022 | $30.00 → $15.25 | Overweight → Neutral | Cantor Fitzgerald |
| 2/25/2022 | $22.00 → $14.00 | Buy | Needham |
| 11/5/2021 | $24.00 → $22.00 | Buy | Needham |
| 8/5/2021 | $26.00 → $24.00 | Buy | Needham |
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
Citigroup downgraded Aerie Pharma from Buy to Neutral and set a new price target of $15.25 from $14.00 previously
Needham downgraded Aerie Pharma from Buy to Hold
Cantor Fitzgerald downgraded Aerie Pharma from Overweight to Neutral and set a new price target of $15.25 from $30.00 previously
Needham reiterated coverage of Aerie Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $22.00 previously
Needham reiterated coverage of Aerie Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $24.00 previously
Needham reiterated coverage of Aerie Pharmaceuticals with a rating of Buy and set a new price target of $24.00 from $26.00 previously
HC Wainwright resumed coverage of Aerie Pharmaceuticals with a rating of Buy
Needham & Company LLC initiated coverage of Aerie Pharmaceuticals with a rating of Buy and set a new price target of $26.00